Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

CNS Stimulants: Psychedelic Agents01:22

CNS Stimulants: Psychedelic Agents

286
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
286
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

408
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
408
Hallucinogens and Psychedelics01:27

Hallucinogens and Psychedelics

311
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
311
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

859
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
859
Drug Therapy01:28

Drug Therapy

113
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
113
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

710
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
710

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

[Psychotropic drug research in Germany: challenges of early benefit assessment and precision psychiatry].

Der Nervenarzt·2026
Same author

Kynurenine pathway profiles as markers of ketamine response in treatment-resistant depression.

Brain, behavior, and immunity·2026
Same author

Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2026 - Pharmacokinetic, pharmacogenetic and clinical aspects.

Pharmacopsychiatry·2026
Same author

Therapeutic Drug Monitoring of Cannabinoids: Therapeutic Reference Ranges for Delta-9-tetrahydrocannabinol in Medical Cannabis, Nabiximols, Dronabinol and Nabilone.

Pharmacopsychiatry·2026
Same author

German Society of Nuclear Medicine procedure guideline for brain perfusion SPECT using 99mTc-labelled radiopharmaceuticals (09/2025).

Nuklearmedizin. Nuclear medicine·2026
Same author

Long-Term Efficacy of Psilocybin with Adjunct Psychotherapy in Treatment-Resistant Major Depression (EPIsoDE): 6- and 12-Month Naturalistic Follow-Up of a Phase 2b Trial.

Psychotherapy and psychosomatics·2026

Related Experiment Video

Updated: Oct 5, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.5K

[Are psychedelics fast acting antidepressant agents?]

Gerhard Gründer1, Manuela Brand2, Laura Kärtner2

  • 1Zentralinstitut für Seelische Gesundheit, Abteilung für Molekulares Neuroimaging, Medizinische Fakultät Mannheim, Universität Heidelberg, 68159, Mannheim, Deutschland. gerhard.gruender@zi-mannheim.de.

Der Nervenarzt
|February 1, 2022
PubMed
Summary

Psychedelics like psilocybin show rapid antidepressant effects, potentially within one day. Further research is ongoing to confirm their long-lasting benefits for depression.

Keywords:
DepressionOnset of actionPsilocybinPsychedelic-assisted psychotherapyPsychedelics

More Related Videos

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

604
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.0K

Related Experiment Videos

Last Updated: Oct 5, 2025

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density
09:10

DetectSyn: A Rapid, Unbiased Fluorescent Method to Detect Changes in Synapse Density

Published on: July 22, 2022

3.5K
Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression
07:58

Behavioral and Network Pharmacology-Based Analyses for the Traditional Mongolian Medicine Zadi-5 in a Rat Model of Depression

Published on: February 24, 2023

604
Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome
08:49

Rapid In Situ Hybridization using Oligonucleotide Probes on Paraformaldehyde-prefixed Brain of Rats with Serotonin Syndrome

Published on: September 23, 2015

9.0K

Area of Science:

  • Psychiatry
  • Neuroscience

Background:

  • Psychedelics, particularly psilocybin, are emerging as promising psychiatric therapeutics.
  • Their potential for rapid antidepressant effects is under investigation.

Purpose of the Study:

  • To evaluate the speed of antidepressant action of psychedelics.
  • To review clinical studies on psychedelics for depressive syndromes.

Main Methods:

  • Literature review of clinical studies on psychedelics in depressive syndromes.
  • Focus on studies from before the 1960s prohibition and after 2000.
  • Analysis of studies meeting modern methodological standards since 2016.

Main Results:

  • Studies since 2016, primarily using psilocybin, suggest rapid antidepressant onset within one day.
  • These effects are noted for depression, treatment-resistant depression, and cancer-related depression.
  • Current studies involve small sample sizes (<200 patients) and some methodological limitations.

Conclusions:

  • Available evidence suggests potent, rapid, and often long-lasting antidepressant effects of psychedelics.
  • Ongoing trials with larger patient numbers will provide definitive insights into psilocybin's efficacy for depression.